ELIC — Elicera Therapeutics AB Balance Sheet
0.000.00%
Last trade - 00:00- SEK270.83m
- SEK245.98m
- SEK10.86m
Annual balance sheet for Elicera Therapeutics AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | SAS | SAS | SAS | SAS | — |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 52.4 | 43.8 | 29.4 | 26.4 | 24.8 |
| Net Total Receivables | 0.204 | 1.98 | 0.784 | 1.17 | 2.57 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 54.2 | 45.8 | 30.2 | 27.6 | 27.4 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 54.7 | 46.3 | 30.2 | 27.6 | 27.4 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2.5 | 13.5 | 13.8 | 6.8 | 4.06 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 2.5 | 13.5 | 13.8 | 6.8 | 4.06 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 52.2 | 32.8 | 16.4 | 20.8 | 23.4 |
| Total Liabilities & Shareholders' Equity | 54.7 | 46.3 | 30.2 | 27.6 | 27.4 |
| Total Common Shares Outstanding |